Seroprevalence of SARS-CoV-2 and Risk Assessment Among Healthcare Workers at a Dedicated Tertiary Care COVID-19 Hospital in Delhi, India: A Cohort Study

Pragy Sharma 1, Rohit Chawla 2, Saurav Basu 3, Sonal Saxena 2, Warisha Mariam 1, Pradeep Kumar Bharti 2, Shivani Rao 1, Neha Tanwar 1, Anisur Rahman 4, Mohammad Ahmad 5

1. Community Medicine, Maulana Azad Medical College, New Delhi, IND 2. Microbiology, Maulana Azad Medical College, New Delhi, IND 3. Academics, Indian Institute of Public Health, New Delhi, IND 4. Health and Research Emergency, World Health Organization, New Delhi, IND 5. Research, World Health Organization, New Delhi, IND

Abstract

Background

Healthcare workers (HCWs) have a substantially higher risk of Covid-19 infection but there is a paucity of information on the risk factors of disease transmission in high-burden real-world settings.

The study objective was to determine the seroprevalence of SARS-CoV-2 among healthcare workers in a high-burden Covid-19 setting and to estimate the incidence and identify the risk factors of infection.

Methods

This was a prospective observational cohort study amongst doctors and nurses working at a dedicated Covid-19 tertiary care government hospital in Delhi, India. A baseline blood sample (2-3ml) was collected from all the participants to test for the presence of total SARS-CoV-2 antibodies. The HCWs that were seronegative (non-reactive) at baseline were followed-up for ≥21≤28 days with the collection of a second blood sample to assess for the incidence of SARS-CoV-2 infection.

Results

A total of 321 (51.3%, 95% C.I 47.4, 55.3) HCWs were detected with SARS-CoV-2 antibodies on baseline examination. The seroprevalence, when adjusted for assay characteristics, was 54.5% (95% C.I 50.3, 58.6). On bivariate analysis, SARS-CoV-2 antibody positivity lacked statistically significant association with either age, sex, occupation, cumulative duty duration, and smoking status. The incidence of seroconversion in the baseline seronegative cohort on follow-up after 21-28 days was observed in 35 (14.9%) HCWs (n=245). Furthermore, the self-reported adherence to infection prevention and control measures did not show a statistically significant association with antibody positivity in the HCWs, neither at baseline nor on follow-up.

Conclusions

The high risk of SARS-CoV-2 transmission in HCWs may be substantially reduced by adherence to Infection Prevention Control (IPC) and protective measures.

Categories: Preventive Medicine, Public Health, Epidemiology/Public Health

Keywords: India, seroconversion, seroprevalence, covid-19, sars-cov-2

Introduction

The coronavirus disease 2019 (COVID-19) pandemic caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virus has caused more than 189,257,791 cases and 4,070,341 deaths worldwide. In India, the SARS-CoV-2 has been attributed to causing in excess of 31,026,829 cases and 412,531 deaths to date [1, 2].

Healthcare workers (HCWs) including doctors, nurses and other paramedical staff constituting the frontline workforce of a medical health system inevitably experience prolonged periods of direct contact with COVID-19 patients during patient care and management, especially during procedures involving aerosol generation [3, 4]. The prolonged exposure to the virus among HCWs may increase their susceptibility to contracting the SARS-CoV-2 infection compared to the general population. However, the risk of infection may be reduced by adherence to the recommended non-pharmaceutical interventions including social distancing, masking, and hand hygiene, in addition to the appropriate use of personal protective equipment [5].

How to cite this article

Sharma P, Chawla R, Basu S, et al. (December 29, 2021) Seroprevalence of SARS-CoV-2 and Risk Assessment Among Healthcare Workers at a Dedicated Tertiary Care COVID-19 Hospital in Delhi, India: A Cohort Study. Cureus 13(12): e20805. DOI 10.7759/cureus.20805
Safeguarding HCWs against SARS-CoV-2 represents a pivotal public health goal to ensure the capacity of the healthcare system to deliver uninterrupted services to the affected population, and to prevent transmission of infection from infected HCWs to their colleagues, patients, and the community [6, 7].

The detection of SARS-CoV-2 antibodies in individuals signifies the presence of a previous infection from the virus with the ensuing clinical spectrum being mostly asymptomatic or mild presentation in 85% cases, with moderate and severe presentation in the remainder [8]. SARS-CoV-2 seroprevalence surveys screen for antibodies in individuals to assess for the spread of infection in the population and for identifying sociodemographic and clinical factors associated with the risk of infection [9]. Galanis et al on pooled analysis from worldwide studies observed the seroprevalence of antibodies in HCWs as 8.7% (95% CI 6.7-10.9%), with risk factors of infection recognized to be suboptimal hand hygiene before and after patient contact, longer work hours, and improper personal protective equipment (PPE) usage [10]. Seroprevalence studies in HCWs have indicated the presence of SARS-CoV-2 antibodies ranging from 4% to 22% globally, although there are very few studies that have been conducted in India and none with a prospective design to estimate the incident risk [11-16].

The World Health Organization (WHO) has recommended the conduct of serial serosurveys to assess the extent of COVID-19 infection in a specified population and understand the risk factors and the dynamics of infection transmission [9]. Estimating the seroprevalence, trends, and identifying the risk factors of infection in a high burden Covid-19 hospital setting is necessary for understanding the factors contributing to virus transmissibility, especially in the local geographic context considering the prevalent virus strains.

With this background, we conducted this study with the objectives of determining the seroprevalence of SARS-CoV-2 among healthcare workers in a dedicated tertiary care government hospital, and ascertaining the incidence and risk factors of infection.

**Materials And Methods**

**Study design, setting, and participants**

This was a prospective observational cohort study of healthcare workers (HCWs) working in a dedicated 2200-bedded COVID-19 Care Centre in a metro city, which has managed over 20,000 moderate-to-severe COVID-19 cases since April 2020 [17]. The data were collected from 2 December 2020 to 25 May 2021.

The study participants were HCWs comprising either doctors or nurses who were involved in the provision of care to any laboratory-confirmed COVID-19 patient, either through real-time polymerase chain reaction (PCR) or antigen assay, following their admission and navigation through various departments of the hospital as part of the continuum of care. We included those HCWs who were currently deployed at any COVID-19 ward or intensive care unit of Lok Nayak Hospital (LNH) and were involved in the clinical management of any laboratory-confirmed COVID-19 patient. The participants were enrolled irrespective of the presence of any symptoms of suspected COVID-19-like illness at the time of recruitment. However, the HCWs who reported any laboratory-confirmed COVID-19 case among their close contacts at the time of recruitment were excluded. Doctors and nurses were posted for shifts of 15-day duties at the ICUs and wards followed by a minimum duration of 7 days of quarantine usually offered at designated hotels and hostels.

**Outcome, sample size, and sampling strategy**

The primary outcome was the proportion of study participants who have serological evidence (anti-SARS-CoV-2 total antibody) of SARS-CoV-2 infection at baseline, and the incidence of SARS-CoV-2 infection in the seronegative cohort during follow-up.

The sample size for the cross-sectional analysis is adequate considering the seroprevalence of IgG SARS-CoV-2 antibody in doctors and nurses as 7.7% based on a previous study in the same institution during August-September 2020, at 95% confidence levels, 2% absolute precision, and 5% non-response was estimated to be 630 [18]. For the cohort analysis, at 95% confidence level, 80% power, assuming the ratio of unexposed and exposed to be 1 (since exposure could not be determined in those using PPE), expecting infection in the exposed group (high-risk HCWs) to be 5.4% and unexposed group (low-risk HCWs) to be 1.2% from a study in Germany, and considering 10% loss to follow-up, the sample size was calculated to be 566 on applying the Fleiss formula [19].

The sampling strategy was based on simple random sampling at the ward/ICU level for the selection of the study participants. There are 32 wards and intensive care units in LNH with ~1400 doctors and nurses involved in the management of COVID-19 patients who are posted for duty on a rotation basis as per the duty roster. HCWs, including doctors and nurses meeting the eligibility criteria, were recruited from these wards and ICUs. On each day of data collection, one ward/ICU was selected by simple random sampling using computer-generated random numbers. The sampling frame was generated from the doctor and nurse’s duty roster for the fortnight after excluding previously enrolled or non-responsive HCWs. Within the ward, on each day, a total of eight eligible HCWs were recruited in the study through the lottery method with additional HCWs contacted in case of non-response.
Data collection

Data instruments used in this study included an interview schedule to collect sociodemographic information of the participants. The information on adherence to infection prevention and control measures and contact with and type of exposure to the COVID-19 patients following their admission to the health care facility were measured at baseline and on follow-up using Forms 1 and 2, respectively. The symptom diary captured the onset and duration of symptoms related to COVID-19-like illness among the seronegative participants at baseline during a period of telephonic follow-up lasting at least 21 days until the follow-up sample collection. A participant was considered as symptomatic if they had any one of the following symptoms for a period of ≥1 day: fever, sore throat, cough, runny nose, shortness of breath, chills, vomiting, nausea, diarrhoea, conjunctivitis, rash, headache, muscle aches, joint ache, loss of appetite, loss of smell, nose bleed, and fatigue.

Laboratory evaluation and processing

We collected a baseline blood sample (2-3ml) from all the study participants to test for the presence of total SARS-CoV-2 antibodies. The HCWs that were seronegative (non-reactive) were followed-up for ≥21≤28 days with the collection of a second blood sample to assess the incidence of SARS-CoV-2 infection. All the staff involved in the collection, transportation, processing, and storage of specimens were trained in safe handling practices and spill decontamination procedures. For each blood sample collected, the time of collection, the conditions for transportation, and the time of arrival at the laboratory were recorded. Specimens were sent to the laboratory immediately upon collection.

Anti-SARS-CoV-2 total antibody was detected in the serum samples using Wantai™ SARS-CoV-2-Ab ELISA kit (Beijing Wantai Biological, Beijing, China), an enzyme-linked immunosorbent assay (ELISA) for the qualitative detection of total antibodies to SARS-CoV-2 virus in human serum or plasma specimens. The assay is a two-step incubation antigen “sandwich” enzyme immunoassay, which uses polystyrene microwell strips pre-coated with recombinant SARS-CoV-2 antigen. The specificity of the assay kit was 100% and the sensitivity was 94.7% as per kit literature.

Statistical analysis

Data was managed in EpiData manager using EpiData entry client (single-entered) (EpiData Association, Odense, Denmark). The data was analysed using STATA 14 (StataCorp, College Station, USA). The results were expressed in frequency and proportions for categorical variables, mean and standard deviation for normally distributed, and median and interquartile range for non-normal data representation of the continuous variables. Seroprevalence estimates were reported as proportions with 95% confidence intervals. The apparent (crude) seroprevalence was adjusted for the assay characteristics using the formula for True (Adjusted) prevalence = Apparent seroprevalence + (Specificity - 1) / [Specificity + Sensitivity - 1] [20]. The association between categorical variables was assessed using the Chi-square test. A p-value < 0.05 was considered statistically significant.

Ethical considerations

The study was approved by the Institutional Ethics Committee (F.1/IEC/MAMC/(79/07/2020/No203). Written and informed consent was obtained from all the study participants. The reports of antibody testing were intimated to each participant individually with confidentiality maintained at all stages of the study.

Results

Participant characteristics

We recruited a total of 625 HCWs participants comprising 202 doctors and 423 nurses with a net response rate of 92.7% (Figure 1).
The mean (SD) age of the HCWs was 36.7 (9.5 years) including 253 (40.5%) males and 372 (59.5%) females. Faculty doctors comprised only 18 (2.9%) while senior and mid-level nurses comprised 132 (21.1%) and 213 (34.1%) of the participants, respectively. The cumulative duration of prior ward or ICU-related COVID-19 duty in the previous 6 months was <15 days in 392 (62.9%), between 15-60 days in 80 (12.5%), and ≥61 days in 153 (24.5%) HCWs. A total of 136 (21.8%) participants had a history of COVID-19 infection diagnosed with real-time PCR or antigen tests, of which 26 (19.1%), 82 (60.3%), 22 (16.2%), and 6 (4.4%) HCWs had asymptomatic, mild, moderate and severe disease, respectively. The most common pre-existing chronic disease conditions in the HCWs were obesity 42 (6.7%), lung disease 40 (6.4%), diabetes 27 (4.3%), heart disease 22 (3.5%), and liver disease 5 (0.8%).

Seroprevalence of SARS-CoV-2 and its predictors

A total of 321 (51.3%, 95% C.I 47.4, 55.3) HCWs were detected with total antibodies to SARS-CoV-2 on baseline examination. The seroprevalence, when adjusted for assay characteristics, was 54.5% (95% C.I 50.3, 58.6).

On bivariate analysis, SARS-CoV-2 antibody positivity lacked statistically significant association with either age, sex, occupation, cumulative duty duration, or smoking status. However, the HCWs with a history of prior COVID-19 had 11.66 times higher odds of seropositivity. Participants who had received vaccination with two doses of either COVID-19 vaccine (n=43) had 100% seroprevalence at baseline, while those who received a single vaccine dose also had 5.8 times higher odds of seropositivity compared to the non-vaccinated HCWs. The seropositivity amongst the HCWs working in the gynaecology and intensive care departments was also higher compared to the other departments. (Table 1)

| Characteristic | Total | SARS-CoV-2 Seropositive | Unadjusted odds | p-value |
|----------------|-------|------------------------|----------------|---------|
|                |       |                        |                |         |

FIGURE 1: Flow diagram of the recruitment of participants

*25 doctors and 29 nurses refused for baseline sample.

*25 doctors and 34 nurses refused for follow up samples (3 HCWs developed COVID-19 infection confirmed with real time PCR prior to their follow-up).
| TABLE 1: Factors associated with seropositivity (SARS-CoV-2 total antibody positive) in study participants at baseline (N=625)

ILI: influenza-like illness; ENT: ear nose throat | No. (%) | No. (%) | 95% CI | P-value |
|---|---|---|---|---|
| **Age** | | | | |
| Mean (SD) | 36.8 (10.1) | | 0.99 (0.97, 1.00) | 0.104 |
| **Sex** | | | | |
| Male | 253 (40.5) | 131 (51.8) | 1 | 0.863 |
| Female | 372 (59.5) | 190 (51.1%) | 0.97 (0.71, 1.34) | |
| **Occupation** | | | | |
| Doctor | 203 (32.48) | 111 (54.7) | 1 | 0.25 |
| Nurse | 422 (67.5) | 210 (49.6) | 0.82 (0.59, 1.15) | |
| **Duty duration** | | | | |
| <2 months | 472 (75.5) | 251 (53.2) | 1 | 0.081 |
| ≥2 months | 149 (23.8) | 67 (45.0) | 0.72 (0.50, 1.04) | |
| **History of Covid-19 infection** | | | | |
| Present | 136 (21.8) | 121 (89.0) | 11.66 (6.62, 20.53) | <0.001 |
| Absent | 489 (78.2) | 200 (40.9) | 1 | |
| **ILI Symptoms** | | | | |
| Present | 64 (10.2) | 34 (53.1) | 1 | 0.766 |
| Absent | 561 (89.8) | 287 (53.1) | 1.08 (0.64, 1.82) | |
| **Smoker** | | | | |
| Yes | 22 (3.5) | 14 (63.6) | 1.69 (0.70, 4.08) | 0.246 |
| No | 603 (96.5) | 307 (50.9) | 1 | |
| **Vaccination status** | | | | |
| Complete | 43 (6.9) | 43 (100) | 110 (6.7, 1799.6) | |
| Partial | 56 (8.9) | 46 (82.1) | 5.8 (2.9, 11.9) | <0.001 |
| Non-vaccinated | 526 (84.2) | 232 (44.1) | 1 | |
| **Department** | | | | |
| Casualty | 43 | 23 (53.5) | - | - |
| ENT | 6 | 3 (50) | - | - |
| Emergency | 29 | 9 (31) | - | - |
| Gynaecology | 69 | 45 (65.2) | - | - |
| ICU/Anaesthesia | 134 | 74 (55.2) | - | - |
| Medical Ward | 72 | 31 (43) | - | - |
| Neurology | 16 | 9 (56.2) | - | - |
| Surgery | 138 | 64 (46.4) | - | - |
| Orthopaedics | 14 | 8 (57.1) | - | - |
| Others | 48 | 26 (54.2) | - | - |
Table 2 presents the data on adherence to infection prevention and control measures in the study participants at baseline. Most participants reported adherence to the recommended hand hygiene measures after touching the patient, before aseptic procedures, after body fluid exposure, and after touching the patient’s surroundings. Furthermore, most participants (99.7%) reported adequate availability of PPE in sufficient quantity at all times in their healthcare facility. The utilization of PPE by the HCWs on COVID-19 duty indicated near-universal use of respirators and face shields with suboptimal use of goggles during face-to-face contact, aerosolizing procedures, and when coming in contact with body fluids (Figures 2,3,4).

However, the self-reported adherence to Infection Prevention Control (IPC) measures did not show a statistically significant association with antibody positivity in the HCWs. (Table 3)

| Infection Prevention Control measure | Total | Doctors | Nurses |
|-------------------------------------|-------|---------|--------|
| Hand Hygiene                         |       |         |        |
| Always                              | 539 (87.2) | 168 (83.2) | 371 (89.2) |
| Most of the time                     | 71 (11.5)  | 32 (15.8)   | 39 (9.4)   |
| Occasionally                        | 7 (1.1)  | 2 (1)     | 5 (1.2)   |
| Rarely                              | 1 (0.2)  | 0 (0)     | 1 (0.2)   |
| Missing                             | 7 (1.1) | 1 (0.5)   | 6 (1.4)   |
| Use Alcohol based hand rub before touching patient |       |         |        |
| Always                              | 502 (80.6) | 155 (76.4) | 347 (82.6) |
| Most of the time                     | 83 (13.3)  | 40 (19.7)   | 43 (10.2)  |
| Occasionally                        | 25 (4.0)  | 5 (2.5)    | 20 (4.8)   |
| Rarely                              | 13 (2.1)  | 3 (1.5)    | 10 (2.4)   |
| Missing                             | 2(0.32)  | 0         | 2(0.5)    |
| Use Alcohol based hand rub before cleaning/aseptic procedures |       |         |        |
| Always                              | 509 (81.7) | 164 (80.8) | 345 (82.1) |
| Most of the time                     | 78 (12.5)  | 33 (16.3)   | 45 (10.7)  |
| Occasionally                        | 25 (4.0)  | 4 (2.0)    | 21 (5)     |
| Rarely                              | 11 (1.8)  | 2 (1.0)    | 9 (2.1)    |
| Missing                             | 2(0.3)  | 0         | 2(0.5)    |
| Use Alcohol based hand rub after (risk of) body fluid exposure |       |         |        |
| Always                              | 506 (81.2) | 170 (83)   | 336 (80)   |
| Most of the time                     | 71 (11.4)  | 26 (12.8)   | 45 (10.7)  |
| Occasionally                        | 26 (4.2)  | 5 (2.5)    | 21 (5)     |
| Rarely                              | 20 (3.2)  | 2 (1)      | 18 (4.3)   |
| Missing                             | 2(0.3)  | 0         | 2(0.5)    |
| Use Alcohol based hand rub after touching patient |       |         |        |
| Always                              | 505 (81.2) | 163 (80.3) | 342 (81.6) |
| Most of the time                     | 76 (12.2)  | 35 (17.2)   | 41 (9.8)   |
| Occasionally                        | 24 (3.9)  | 2 (1.0)    | 22 (5.3)   |
| Rarely                              | 17 (2.7)  | 3 (1.5)    | 14 (3.3)   |
| Missing                             | 3(0.5)  | 0         | 3(0.7)    |
| Use Alcohol based hand rub after touching patient’s surroundings |       |         |        |
### TABLE 2: Adherence to Infection Prevention and Control measures at Baseline (N=625)

| IPC standard precautions when in contact with any patient | Always | Most of the time | Occasionally | Rarely | Don’t know | Missing |
|----------------------------------------------------------|--------|------------------|--------------|--------|------------|---------|
| Always                                                   | 506 (81.5) | 160 (79.2) | 346 (82.6) | 9 (1.5) | 13 (2.1) | 4(0.6) |
| Most of the time                                         | 76 (12.2)  | 35 (17.3)  | 41 (9.8)   | 2 (0.4) | 2 (1)   | 1(0.4) |
| Occasionally                                             | 17 (2.7)   | 4 (2.0)     | 13 (3.1)   | 8 (1.9) | 11 (2.1) | 1(0.4) |
| Rarely                                                   | 9 (1.5)    | 1 (0.5)     | 8 (1.9)    | 2 (0.4) | 2 (1)   | 1(0.4) |
| Don’t know                                               | 13 (2.1)   | 2 (1)       | 12 (2.9)   | 1 (0.5) | 11 (2.1) | 1(0.4) |
| Missing                                                  | 4(0.6)     | 1(0.4)      | 4(0.9)     | 0      | 4(0.9)  | 0 |

| Wear PPE when indicated                                  | Always | Most of the time | Occasionally | Rarely | Don’t know | Missing |
|----------------------------------------------------------|--------|------------------|--------------|--------|------------|---------|
| Always                                                   | 579 (92.7) | 186 (91.5) | 379 (96.1) | 10 (1.6) | 11 (1.8) | 2(0.3) |
| Most of the time                                         | 31 (5)   | 18 (8.9) | 13 (3.1)   | 8 (1.3) | 12 (1.9) | 2(0.3) |
| Occasionally                                             | 9 (1.4) | 1 (0.5) | 8 (1.9)    | 2 (0.4) | 11 (1.8) | 2(0.3) |
| Rarely                                                   | 14 (2.3) | 3 (1.5) | 12 (2.9)   | 3 (0.5) | 11 (1.8) | 2(0.3) |
| Don’t know                                               | 2 (0.3) | 1 (0.5) | 11 (2.1)   | 2 (0.4) | 11 (1.8) | 2(0.3) |
| Missing                                                  | 1(0.2) | 0 | 2(0.3) | 0 | 2(0.3) | 0 |

**FIGURE 2: Distribution of utilization of PPE during various exposure to COVID-19 infected patients**

PPE: Personal protective equipment
FIGURE 3: Distribution of utilization of PPE while conducting aerosolized procedure to COVID-19 infected patients

PPE: Personal protective equipment

FIGURE 4: Distribution of utilization of PPE during exposure to body fluid of COVID-19 infected patients

PPE: Personal protective equipment

| IPC                | SARS-CoV-2 Seropositive (n=321) | SARS-CoV-2 Seronegative (n=304) | Unadjusted odds | p-value |
|--------------------|----------------------------------|---------------------------------|-----------------|---------|
| Hand hygiene       |                                  |                                 |                 |         |
| Always             | 271(84.4)                        | 268(88.1)                       |                 |         |
| Most of the time   | 43(13.4)                         | 28(9.2)                         | 1               |         |
| Sometimes          | 4(1.2)                           | 3(0.9)                          | 1.5(0.9,2.5)    | 0.25    |
| Rarely             | 0                                | 1(0.3)                          | 1.3(0.2,5.9)    |         |
|                                   | Always | Most of the time | Sometimes | Rarely | Missing |
|-----------------------------------|--------|------------------|-----------|--------|---------|
| Hand hygiene before touching the patient |        |                  |           |        |         |
| Always                            | 255(79.4) | 247(81.2)        | 1         | 0.15   |
| Most of the time                  | 48(14.9)  | 35(11.5)         | 1.3(0.8,2.1) |
| Sometimes                         | 14(4.3)   | 11(3.6)          | 1.2(0.5,2.7) |
| Rarely                            | 3(0.9)    | 10(3.2)          | 0.2(0.1,1.1) |
| Missing                           | 1(0.3)    | 1(0.3)           | 0         |
| Hand hygiene before an aseptic procedure |        |                  |           |        |         |
| Always                            | 255(79.4) | 254(83.5)        | 1         |         |
| Most of time                      | 47(14.6)  | 31(10.2)         | 1.5(0.9,2.4) | 0.11  |
| Sometimes                         | 15(4.6)   | 10(3.2)          | 1.4(0.6,3.3) |
| Rarely                            | 3(0.9)    | 8(2.6)           | 0.3(0.1,1.4) |
| Missing                           | 1(0.3)    | 1(0.3)           | 0         |
| Hand hygiene after body fluid exposure |        |                  |           |        |         |
| Always                            | 252(78.5) | 254(83.5)        | 1         |        |
| Most of time                      | 45(14)    | 26(8.5)          | 1.7(1,2.9)  |
| Sometimes                         | 15(4.6)   | 11(3.6)          | 1.3(0.6,3)   | 0.11  |
| Rarely                            | 8(2.4)    | 12(3.9)          | 0.6(0.2,1.6) |
| Missing                           | 1(0.3)    | 1(0.3)           | 0         |
| Hand hygiene after touching patient |        |                  |           |        |         |
| Always                            | 258(80.3) | 247(81.2)        | 1         |        |
| Most of time                      | 45(14)    | 31(10.2)         | 1.3(0.8,2.2) | 0.54  |
| Sometimes                         | 11(3.4)   | 13(4.2)          | 0.8(0.3,1.8) | 0.15  |
| Rarely                            | 5(1.5)    | 12(3.9)          | 0.3(0.1,1.1) |
| Missing                           | 2(0.6)    | 1(0.3)           | 0         |
| Hand hygiene after touching patient's surrounding |        |                  |           |        |         |
| Always                            | 251(78.1) | 244(80.2)        | 1         |        |
| Most of time                      | 45(14)    | 32(10.5)         | 1.3(0.8,2.2) | 0.54  |
| Sometimes                         | 17(5.3)   | 18(5.9)          | 0.9(0.4,1.8) |
| Rarely                            | 6(1.8)    | 8(2.6)           | 0.7(0.2,2.1) |
| Missing                           | 2(0.6)    | 2(0.6)           | 0         |
| Follow IPC standard precautions   |        |                  |           |        |         |
| Always                            | 252(78.5) | 254(83.55)       | 1         |        |
| Most of time                      | 44(13.7)  | 32(10.5)         | 1.3(0.8,2.2) | 0.35  |
| Sometimes                         | 12(3.7)   | 5(1.6)           | 2.4(0.8,6.9) |
| Rarely                            | 4(1.2)    | 5(1.6)           | 0.8(0.2,3)  |
| I don't know                      | 7(2.1)    | 6(1.9)           | 1.1(0.3,3.5) |
| Missing                           | 2(0.6)    | 2(0.6)           | 0         |
Seroconversion with SARS-CoV-2 and risk factors

The incidence of seroconversion in the baseline seronegative cohort on follow-up after 21-28 days (median 24 days) was observed in 35 (14.9%) HCWs (n=245). The overall incidence rate of SARS-CoV-2 seropositivity was 5.9 (95% CI 4.2, 8.2) per 1000 person-days. Among the baseline seronegative HCWs on follow-up, complete vaccination with two doses of either Covishield (AZD1222) or Covaxin (BBV152) vaccine was the only factor that was significantly associated with seroconversion indicating the presence of detectable antibodies (p<0.001) (Table 4). Furthermore, the difference in the proportion of HCWs adherence to the IPC measures did not significantly vary among the seropositive and the seronegative subgroups on follow-up. (Table 5)
| Characteristic                  | Total  | SARS-CoV-2 Seropositive (Incidence of infection) | Relative Risk (95% C.I) | p-value |
|--------------------------------|--------|------------------------------------------------|-------------------------|---------|
| Age Mean (SD)                  | 37.4 (9.8) | -                                              |                         |         |
| Sex Male                       | 90 (37.2) | 12 (13.3)                                      | 0.88 (0.46, 1.68)       | 0.701   |
| Female                         | 152 (62.8) | 23 (15.1)                                      | 1                       |         |
| Occupation Doctor              | 65 (26.9) | 11 (16.9)                                      | 1.21 (0.56, 2.65)       | 0.63    |
| Nurse                          | 177 (73.1) | 24 (13.6)                                      | 1                       |         |
| Duty duration <2 months        | 178 (73.9) | 27 (15.2)                                      | 1.07 (0.51, 2.24)       | 0.849   |
| ≥2 months                      | 63 (26.1) | 8 (12.7)                                       | 1                       |         |
| History of Covid-19 infection  |        |                                                |                         |         |
| Present                        | 10 (4.1)  | 3 (30.0)                                       | 1                       | 0.16    |
| Absent                         | 232 (95.9) | 32 (14.1)                                      | 2.68 (0.66, 10.69)      |         |
| ILI Symptoms                   |        |                                                |                         |         |
| Present                        | 25 (10.3) | 1 (4.00)                                       | 1                       | 0.15    |
| Absent                         | 217 (89.7) | 34 (15.7)                                      | 0.26 (0.04, 1.78)       |         |
| Smoker                         |        |                                                |                         |         |
| Yes                            | 5 (2.1)   | 0 (0)                                          | -                       | -       |
| No                             | 237 (97.9) | 35 (14.8)                                      | -                       | -       |
| Vaccination status             |        |                                                |                         |         |
| Complete                       | 47 (19.2) | 17 (36.2)                                      | 6.0 (2.7, 13.5)         | <0.001  |
| Partial                        | 35 (14.3) | 4 (11.4)                                       | 1.4 (0.42, 4.45)        |         |
| Unvaccinated                   | 163 (66.5) | 14 (8.5)                                       | 1                       |         |

**TABLE 4: Factors associated with seropositivity at follow up (N= 245)**

*59 lost to follow-up

ILI: influenza-like illness
Symptoms suggestive of COVID-19 were non-specific and did not show any statistically significant variation between the SARS-CoV-2 seropositive and the seronegative HCWs at baseline. However, the onset of symptoms was observed in 12 (34.3%, n=35) of the HCWs with evidence of SARS-CoV-2 seroconversion during follow-up assessment. (Table 6)
| Symptom                           | Baseline | Follow-up |
|----------------------------------|----------|-----------|
| Runny nose                       | 15 (4.9) | 17 (5.3)  |
| Shortness of breath              | 6 (2)    | 7 (2.2)   |
| Chills                           | 3 (1)    | 8 (2.5)   |
| Vomiting                         | 4 (1.3)  | 0         |
| Nausea                           | 5 (1.6)  | 3 (0.9)   |
| Diarrhoea                        | 2 (0.7)  | 5 (1.6)   |
| Headache                         | 23 (7.6) | 15 (4.7)  |
| Rash                             | 1 (0.3)  | 3 (0.9)   |
| Conjunctivitis                   | 2 (0.7)  | 3 (0.9)   |
| Muscle aches                     | 20 (6.6) | 24 (7.5)  |
| Joint ache                       | 16 (5.3) | 20 (6.2)  |
| Loss of appetite                 | 7 (2.3)  | 7 (2.2)   |
| Loss of smell or taste           | 5 (1.6)  | 14 (4.4)  |
| Nose bleed                       | 2 (0.7)  | 4 (1.3)   |
| Fatigue                          | 22 (7.2) | 23 (7.2)  |
| Seizures                         | 0        | 0         |

Seronegative (210)  Seropositive (35)

At Follow up (N=245) Symptomatic

| Symptom                           | Baseline | Follow-up |
|----------------------------------|----------|-----------|
| Fever                            | 4 (1.9)  | 1 (2.9)   |
| Sore throat                      | 12 (5.7) | 4 (11.4)  |
| Cough                            | 17 (8.1) | 7 (20)    |
| Runny nose                       | 16 (7.6) | 4 (11.4)  |
| Shortness of breath              | 2 (0.95) | 0         |
| Chills                           | 2 (0.95) | 1 (2.9)   |
| Vomiting                         | 3 (1.4)  | 0         |
| Nausea                           | 1 (0.5)  | 0         |
| Diarrhoea                        | 5 (2.4)  | 3 (8.6)   |
| Rash                             | 1 (0.5)  | 0         |
| Conjunctivitis                   | 0        | 0         |
| Muscle aches                     | 1 (0.5)  | 0         |
| Joint ache                       | 5 (2.4)  | 0         |
| Loss of appetite                 | 1 (0.5)  | 0         |
| Loss of smell (anosmia) or taste | 1 (0.5)  | 0         |
| Nose bleed                       | 0        | 0         |
| Fatigue                          | 4 (1.9)  | 0         |
| Seizures                         | 1 (0.5)  | 0         |

**TABLE 6: Distribution of symptom profile in study participants at baseline and follow-up**
Discussion

The present study was conducted among healthcare workers (HCWs) comprising doctors and nurses posted for COVID-19 duty at a dedicated tertiary care COVID-19 hospital and medical college complex in New Delhi, India. Nearly one in two (51.4%) participants were seropositive at baseline with antibody positivity unrelated to their sociodemographic or clinical characteristics. Despite high usage of PPE which has proven efficacy in the prevention of SARS-CoV-2 infection, the seroconversion in the seronegative participants at baseline was not associated with the self-reported adherence to the standard infection prevention and control measures.

This is one of the first COVID-19 related cohort studies among HCWs in India that was conducted in the real-world setting of a high burden tertiary care COVID-19 hospital, for detection of antibodies suggestive of past infection to SARS-CoV-2, with a majority of the participants being unvaccinated at baseline. Unlike some population-based seroepidemiological studies, the sex of the participants was not associated with seropositivity, probably since the participants had similar age and occupational profile indicating a behavioural rather than biological predisposition to infection [21-24]. Furthermore, the seroprevalence in the HCWs was lower compared to the estimates observed in the general population of the state of Delhi [24]. However, a nationwide Indian serosurvey in the pre-vaccination period observed the SARS-CoV-2 seroprevalence in doctors to be higher than in the general populations [21]. These findings suggest a complex disease transmission mechanism wherein HCWs despite having sustained exposure to SARS-CoV-2 had comparatively lower rates of infection probably due to high adherence to IPC measures especially involving the use of PPE. Another study in the USA by Jacob et al (2021) also reported the absence of workplace factors as a risk factor for seropositivity while community contact in the HCWs was associated with higher seropositivity [23]. In contrast to a study in Europe, in this study HCWs working in the intensive care unit of the hospital had higher seroprevalence compared to the other departments [11].

There are two key implications of this study. First, HCWs in a high-risk environment nearly universally prefer the utilization of PPE for protection against COVID-19. However, the lack of a statistically significant difference in the incidence of infection in the optimal compared to the sub-optimally adherent HCWs suggest either improper use practice, recall bias, or overestimation of the IPC adherence estimates because of the bias induced from social desirability. A recommended alternative methodology would entail frequent observation by trained observers during COVID-19 patient management to assess adherence to IPC during all the potential moments of exposure and the correct usage of PPE. Second, the evaluation of antibody response in healthcare workers post-vaccination, detection of neutralizing antibodies in seropositive participants, and the possibility of considering booster doses in the absence of adequate immune response warrant urgent consideration in this high-risk cohort.

There are certain study limitations. First, the data collection was mostly completed over a period of four months (December-March) when the COVID-19 disease burden was lower in Delhi compared to the subsequent (April-May) period when disease burden was very high as it coincided with a nationwide second wave period of the pandemic fuelled by mutant strains. Moreover, antibody response to SARS-CoV-2 infection is usually induced 1-3 weeks post-infection so the early screening for antibodies may have generated false negative reports in those participants who were infected but tested prior to their seroconversion. Consequently, the seroprevalence estimates obtained in this study are a likely underestimation. Second, the vaccination in HCWs was an effect modifier as it increased the seroprevalence estimates both at baseline and during follow-up. The WantaiTM kit used was unable to differentiate between natural-infection-induced versus vaccine-induced seroconversion. Finally, the possibility of contraction of infection during off-duty hours during community interaction with other HCWs or family members was not ascertained in this study since most HCWs remained in isolation in dedicated hotels and hostels during post-duty hours and subsequently a week thereafter. However, the possibility of infection from sources other than the hospitalized COVID-19 patients cannot be completely ruled out.

Conclusions

Healthcare workers are likely to utilize personal protective equipment (PPE) and follow the IPC precautions when available at their health facilities during the management of COVID-19 patients. High rates of adherence to the use of PPE are also likely to translate into overall lower rates of SARS-CoV-2 infection compared to the general population despite the greater frequency and sustained risk of infection contraction. Healthcare providers providing outpatient services with sustained close contact with patients such as dentists may have a high risk of infection warranting the use of effective PPE in these comparatively low-risk settings. Training of HCWs in the use of PPE may be suboptimal considering the low cumulative training period accorded to the same. Consequently, hospital administrators should provide an enhanced focus on training of HCW for the appropriate use of PPE.

The evaluation of antibody response in healthcare workers post-vaccination and the possibility of considering booster doses in the absence of immune response warrant consideration in this high-risk cohort. Future SARS-CoV-2 serosurveys in HCWs should identify the effectiveness of vaccines in preventing infection, disease, and severe disease in this high-risk group.

This is one of the first COVID-19 related cohort studies among HCWs in India that was conducted in the real-world setting of a high burden tertiary care COVID-19 hospital, for detection of antibodies suggestive of past infection to SARS-CoV-2, with a majority of the participants being unvaccinated at baseline. Unlike some population-based seroepidemiological studies, the sex of the participants was not associated with seropositivity, probably since the participants had similar age and occupational profile indicating a behavioural rather than biological predisposition to infection [21-24]. Furthermore, the seroprevalence in the HCWs was lower compared to the estimates observed in the general population of the state of Delhi [24]. However, a nationwide Indian serosurvey in the pre-vaccination period observed the SARS-CoV-2 seroprevalence in doctors to be higher than in the general populations [21]. These findings suggest a complex disease transmission mechanism wherein HCWs despite having sustained exposure to SARS-CoV-2 had comparatively lower rates of infection probably due to high adherence to IPC measures especially involving the use of PPE. Another study in the USA by Jacob et al (2021) also reported the absence of workplace factors as a risk factor for seropositivity while community contact in the HCWs was associated with higher seropositivity [23]. In contrast to a study in Europe, in this study HCWs working in the intensive care unit of the hospital had higher seroprevalence compared to the other departments [11].

There are two key implications of this study. First, HCWs in a high-risk environment nearly universally prefer the utilization of PPE for protection against COVID-19. However, the lack of a statistically significant difference in the incidence of infection in the optimal compared to the sub-optimally adherent HCWs suggest either improper use practice, recall bias, or overestimation of the IPC adherence estimates because of the bias induced from social desirability. A recommended alternative methodology would entail frequent observation by trained observers during COVID-19 patient management to assess adherence to IPC during all the potential moments of exposure and the correct usage of PPE. Second, the evaluation of antibody response in healthcare workers post-vaccination, detection of neutralizing antibodies in seropositive participants, and the possibility of considering booster doses in the absence of adequate immune response warrant urgent consideration in this high-risk cohort.

There are certain study limitations. First, the data collection was mostly completed over a period of four months (December-March) when the COVID-19 disease burden was lower in Delhi compared to the subsequent (April-May) period when disease burden was very high as it coincided with a nationwide second wave period of the pandemic fuelled by mutant strains. Moreover, antibody response to SARS-CoV-2 infection is usually induced 1-3 weeks post-infection so the early screening for antibodies may have generated false negative reports in those participants who were infected but tested prior to their seroconversion. Consequently, the seroprevalence estimates obtained in this study are a likely underestimation. Second, the vaccination in HCWs was an effect modifier as it increased the seroprevalence estimates both at baseline and during follow-up. The WantaiTM kit used was unable to differentiate between natural-infection-induced versus vaccine-induced seroconversion. Finally, the possibility of contraction of infection during off-duty hours during community interaction with other HCWs or family members was not ascertained in this study since most HCWs remained in isolation in dedicated hotels and hostels during post-duty hours and subsequently a week thereafter. However, the possibility of infection from sources other than the hospitalized COVID-19 patients cannot be completely ruled out.

Conclusions

Healthcare workers are likely to utilize personal protective equipment (PPE) and follow the IPC precautions when available at their health facilities during the management of COVID-19 patients. High rates of adherence to the use of PPE are also likely to translate into overall lower rates of SARS-CoV-2 infection compared to the general population despite the greater frequency and sustained risk of infection contraction. Healthcare providers providing outpatient services with sustained close contact with patients such as dentists may have a high risk of infection warranting the use of effective PPE in these comparatively low-risk settings. Training of HCWs in the use of PPE may be suboptimal considering the low cumulative training period accorded to the same. Consequently, hospital administrators should provide an enhanced focus on training of HCW for the appropriate use of PPE.

The evaluation of antibody response in healthcare workers post-vaccination and the possibility of considering booster doses in the absence of immune response warrant consideration in this high-risk cohort. Future SARS-CoV-2 serosurveys in HCWs should identify the effectiveness of vaccines in preventing infection, disease, and severe disease in this high-risk group.
Additional Information

Disclosures

Human subjects: Consent was obtained or waived by all participants in this study. Institutional Ethics Committee - Maulana Azad Medical College issued approval F.1/IEC/MAMC/(79/07/2020/No203). The study was approved by the Institutional Ethics Committee (F.1/IEC/MAMC/(79/07/2020/No203). Animal subjects: All authors have confirmed that this study did not involve animal subjects or tissue. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: The study was funded by World Health Organization as a part of the Unity Study. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.

Acknowledgements

The authors acknowledge and thank all the study participants for their support during the study period.

References

1. Lai CC, Shih TP, Ko WC, Tang HJ, Hsieh PR: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. Int J Antimicrob Agents. 2020, 55:105924. 10.1016/j.ijantimicag.2020.105924
2. John Hopkins Coronavirus Tracker. (2021). Accessed: July 16, 2021: https://coronavirus.jhu.edu/map.html
3. Suárez-García I, Martínez de Aramayona López MJ, Sáez Vicente A, Lobo Abascal P: SARS-CoV-2 infection among healthcare workers in a hospital in Madrid, Spain. J Hosp Infect. 2020, 106:357-65. 10.1016/j.jhin.2020.07.020
4. Piccoli L, Ferrari P, Plumatti G, et al.: Risk assessment and seroprevalence of SARS-CoV-2 infection in healthcare workers of COVID-19 and non-COVID-19 hospitals in Southern Switzerland. Lance Reg Health Eur. 2021, 1:100013. 10.1016/j.lanepe.2020.100013
5. Müller K, Girl P, Ruhnke M, et al.: SARS-CoV-2 seroprevalence among health care workers: a voluntary screening study in a regional medical center in Southern Germany. Int J Environ Res Public Health. 2021, 18:10.3390/ijerph18085910
6. Houghton C, Meskell P, Delaney H, et al.: Barriers and facilitators to healthcare workers’ adherence with infection prevention and control (IPC) guidelines for respiratory infectious diseases: a rapid qualitative evidence synthesis. Cochrane Database Syst Rev. 2020, 4:CD013582. 10.1002/14651858.CD013582
7. Bandypadyay S, Ratulixon RE, Kadhum M, et al.: Infection and mortality of healthcare workers worldwide from COVID–19: a systematic review. BMJ Glob Health. 2020, 4:5.
8. Alter G, Seder R: The power of antibody-based surveillance. N Engl J Med. 2020, 385:1782-4. 10.1056/NEJMe2028079
9. World Health Organization. Population-based age stratified seroepidemiological investigation protocol for COVID-19 virus infection. (2021). Accessed: July 15, 2021: https://apps.who.int/iris/handle/10665/351656.
10. Galanis P, Vraka I, Fragkou D, Bilali A, Kaitelidou D: Seroprevalence of SARS-CoV-2 antibodies and associated factors in healthcare workers: a systematic review and meta-analysis. J Hosp Infect. 2021, 108:120-34. 10.1016/j.jhin.2020.101949
11. Klevebro S, Rahmam F, Elfström KM, et al.: Risk of SARS-CoV-2 exposure among hospital healthcare workers in relation to patient contact and type of care. Scand J Public Health. 2021, 49:707-12. 10.1177/14034948211022454
12. Buonafine CP, Palatto BN, Leal FB, et al.: High prevalence of SARS-CoV-2 infection among symptomatic healthcare workers in a large university tertiary hospital in São Paulo, Brazil. BMC Infect Dis. 2020, 20:917. 10.1186/s12879-020-05662-8
13. Kantee A, Läiäivi T, Kareinen L, et al.: SARS-CoV-2 infections among healthcare workers at Helsinki University Hospital, Finland, spring 2020: serosurvey, symptoms and risk factors. Travel Med Infect Dis. 2021, 39:101949. 10.1016/j.tmaid.2020.101949
14. García-Basteiro AL, Monculli G, Tortajada M, et al.: Seroprevalence of antibodies against SARS-CoV-2 among health care workers in a large Spanish reference hospital. Nat Commun. 2020, 11:3500. 10.1038/s41467-020-17318-x
15. Kataia Y, Cole M, Duffy E, et al.: Seroprevalence of SARS-CoV-2 IgG antibodies and risk factors in health care workers at an academic medical center in Boston, Massachusetts. Sci Rep. 2021, 11:9694. 10.1038/s41598-021-89107-5
16. Goenka M, Afzalpurkar S, Goenka U, et al.: Seroprevalence of COVID-19 amongst health care workers in a tertiary care hospital of a metropolitan city from India. J Assoc Physicians India. 2020, 68:14-9. 10.1380/japi.2020.348
17. Malhotra V, Bajwa S, Sharma N, Kumar S, Garg S, Dushyant K, Borle A: Outcomes among 10,314 hospitalized COVID-19 patients at a tertiary care government hospital in Delhi, India. J Med Virol. 2021, 93:4553-8. 10.1002/jmv.26956
18. Sharma P, Chawla R, Bakshi R, et al.: Seroprevalence of antibodies to SARS-CoV-2 and predictors of seropositivity among employees of a teaching hospital in New Delhi, India. Osong Public Health Res Perspect. 2021, 12:88-95. 10.24171/jophrp.2021.12.106
19. Korth I, Wilde B, Dolf S, et al.: SARS-CoV-2 seroprevalence in healthcare workers in Germany: a follow-up study. Int J Environ Res Public Health. 2021, 18:10.3390/ijerph18094540
20. Rogan WJ, Gladen B: Estimating prevalence from the results of a screening test. Am J Epidemiol. 1978, 107:71-6. 10.1093/oxfordjournals.aje.a112510
21. Murhekar MV, Bhatnagar T, Thangaraj J, et al.: SARS-CoV-2 seroprevalence among the general population.
and healthcare workers in India, December 2020-January 2021. Int J Infect Dis. 2021, 108:145-55. 10.1016/j.ijid.2021.05.040

22. Murhekar MV, Bhatnagar T, Selvaraju S, et al.: SARS-CoV-2 antibody seroprevalence in India, August-September, 2020: findings from the second nationwide household serosurvey. Lancet Glob Health. 2021, 9:e257-66. 10.1016/S2214-109X(20)30544-1

23. Kshatri JS, Bhattacharya D, Praharaj I, et al.: Seroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys. Epidemiol Infect. 2021, 149:e139. 10.1017/S0950268821000972

24. Sharma N, Sharma P, Basu S, et al.: The seroprevalence and trends of SARS-CoV-2 in Delhi, India: a repeated population-based seroepidemiological study. medRxiv. 2020121320248123

25. Jacob JT, Baker JM, Fridkin SK, et al.: Risk factors associated with SARS-CoV-2 seropositivity among US health care personnel. JAMA Netw Open. 2021, 4:e2111283. 10.1001/jamanetworkopen.2021.1283